Table 3. Comparison of Treatment Classes Analyzed Using Inverse Probability of Treatment Weighting Cox Proportional Hazards Regression Models and Adjustment for Time-Dependent Covariablesa.
| Patient cohort | IL-17 vs TNF inhibitors | IL-12/23 vs TNF inhibitors | IL-17 vs IL-12/23 inhibitors | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unadjusted | IPTW | Unadjusted | IPTW | Unadjusted | IPTW | |||||||
| Crude HR (95% CI) | P value | Weighted HR (95% CI) | P value | Crude HR (95% CI) | P value | Weighted HR (95% CI) | P value | Crude HR (95% CI) | P value | Weighted HR (95% CI) | P value | |
| Psoriasis (n = 16 892) | 0.76 (0.72-0.82) | <.001 | 0.78 (0.73-0.83) | <.001 | 0.73 (0.69-0.77) | <.001 | 0.76 (0.72-0.80) | <.001 | 1.05 (0.98-1.14) | .18 | 1.02 (0.94-1.10) | .58 |
| Psoriatic arthritis (n = 6531) | 0.73 (0.61-0.88) | <.001 | 0.70 (0.58-0.85) | <.001 | 0.92 (0.79-1.07) | .29 | 1.03 (0.89-1.19) | .70 | 0.80 (0.63-1.00) | .05 | 0.69 (0.55-0.87) | <.001 |
Abbreviations: HR, hazard ratio; IL-12/23, interleukin 12 and interleukin 23; IL-17, interleukin 17; IPTW, inverse probability of treatment weighting; TNF, tumor necrosis factor.
a
Includes conventional, synthetic disease-modifying antirheumatic drugs and prednisone.